 |
Disc Medicine
Last updated: October 06, 2024
John Quisel, CEO
USA | Funding: $592.8M (+)
Website: https://www.discmedicine.com
Disc Medicine is a hematology company that hopes can become the first disease-modifying treatment for erythropoietic porphyrias, a family of rare and debilitating genetic disorders caused by dysregulated heme synthesis.
Website: https://www.discmedicine.com
Disc Medicine is a hematology company that hopes can become the first disease-modifying treatment for erythropoietic porphyrias, a family of rare and debilitating genetic disorders caused by dysregulated heme synthesis.
